When Cells Start Acting Like They Understand

Seven years later, it behaves like the neurons of a five-year-old child  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

November 14th, 2025   |   Read Online   Donald Doge On Wednesday, a few hours after I sent out the essay on longevity, I came across an article in The New York Times that stopped me cold. It didn't contradict anything we talked about. It expanded it. It pushed the entire idea of "more time" into territory I didn't think we'd reach this fast. The article opens with a scene that reads like fiction. A long, windowless hallway in Paola Arlotta's Harvard lab… racks of what look like scientific muffin trays… pools of pink nutrient solution… and inside each cavity, translucent nuggets no bigger than peppercorns. They aren't beads. They aren't models. They're organoids, clusters of neurons grown from human skin cells. The oldest ones are seven years old. One organoid can contain more neurons than the entire brain of a honeybee. Here's the part that caught me. As the organoids aged, their neurons didn't stay simple. They behaved like fetal neurons, then newborn neurons, and after years of careful cultivation, their electrical patterns now resemble the neural maturity of a kindergartner. Arlotta is careful to say they are not brains. They are not conscious, not aware, not miniature minds. They are reductionist replicas meant to teach us how neurons grow, wire, misfire, migrate, and repair. But the similarities are close enough that even she acknowledges the responsibility. Seven years of survival. Structured maturation. Electrical activity that looks like development. It's enough to make the line between imitation and emergence feel thinner than it used to. And that's why this article matters. It forces us to confront something bigger than lifespan. If my essay on Wednesday was about time, this one is about the mind. What happens when the building blocks of thought can live outside the body and keep maturing long after the cells they came from should have died? When Neurons Grow Up Without Us The NYT story makes one distinction clear. These organoids are not miniature brains. They are not thinking, not aware, not drifting toward consciousness. Their purpose is simpler and stranger: they show us how neurons grow when they have no body to grow inside of. That's what makes their development so remarkable. What Arlotta's team watched wasn't learning or behavior. It was maturation. It was time expressing itself in tissue. The gene-expression patterns inside the earliest organoids matched those found in fetal brains. Months later, their electrical rhythms shifted to match newborns. Years later, the neurons inside a five‑year‑old organoid fired with the same timing patterns seen in kindergartners. No decision-making. No problem‑solving. Just the choreography of growth, unfolding as if the cells still belonged to a body that no longer exists. Other labs use organoids for the same reason. They're windows into development. When scientists grow organoids from children with certain genetic variants, they see where migration breaks down. They see how a mutation sends neurons sideways instead of forward. They see structure drift before symptoms ever appear. This is the value of organoids at this stage. They don't tell us how the mind works. They tell us how it forms. They reveal the steps, timing, and mistakes at a neurological level. And by isolating those mistakes, researchers are beginning to demonstrate how some of them can be corrected before they develop into lifelong disorders. This is nature's notes left on the table for anyone patient enough to read them. This is where the line between study and possibility begins to bend. If miswired circuits can reveal themselves in a dish, and if those circuits can be corrected in a dish, then we are inching closer to something medicine has never had before. A way to test human neurological repair on human neural tissue before ever touching a patient. What was once a theory is becoming a living dataset. And the more these organoids grow, mature, and connect, the more they force us to reconsider the edges of what a mind is, where it begins, and how it might eventually be repaired. The Moment Cells Start Acting Like They Understand What happens next in the NYT story is where the ground really starts to shift. The organoids stop behaving like isolated clusters of cells and begin to exhibit behaviors more closely resembling those of living systems. They adapt. They respond. They learn. Not in a human sense. But in a way that makes you rethink where the borders of thought begin. In one autism study, neurons within organoids constructed from donated skin cells deviated from their intended course. The wandering wasn't random. It matched the same developmental detours seen in affected children. In another case linked to Timothy syndrome, scientists observed neurons miswiring themselves, forming incorrect connections, and sending signals down the wrong pathways. Then a single drug corrected the entire pattern. A misfiring circuit snapped back into place. The experiment is now on its way toward clinical trials, and the fact that something this precise can happen in tissue grown from a skin cell changes everything about what we once thought was permanent. And this part hits close to home for me. My beautiful nephew is non-verbal autistic, so when I read that a miswired circuit in an organoid could be corrected with a targeted compound, it didn't land as a headline or an investment. It landed as hope. Real, data-backed hope that the architecture of a developing brain might one day be guided instead of guessed at. And organoids aren't staying solitary. Labs are merging them into assembloids, clusters linked together to model the circuits that typically live inside the nervous system. Earlier this year, one team reproduced the full pain pathway: sensory neurons, relay neurons, and brain‑region organoids wired into a tiny chain. When they exposed the sensory cells to the compound that makes chiles hot, the entire pathway fired at once. The system wasn't sentient. It wasn't feeling anything. But it behaved with the logic of something built to interpret the world. Sensors, relays, outputs. Stimulus and response. Then there is Brainoware. A small Indiana University group wired organoids into a platform that could send signals in and read responses out. They trained it on recordings of people saying two different vowels. After a couple of days, the organoids produced electrical patterns distinct enough for a computer to decode which vowel they were reacting to. And as these organoids continue to grow and connect, they won't just teach us how the brain forms or fails. They'll teach us how it might one day be repaired, rebooted, or rebuilt. 🚀 Get Moonshot Alerts Instantly Markets move in minutes. Your inbox can't keep up. Join the Moonshot VIP Text Service and get real-time alerts, portfolio updates, and first-move intelligence directly to your phone. Be first to know. Anywhere. 👉 [Join the Text List →] The New Market Built From Pieces of a Mind Once you see where this is heading, the economic implications start to come into focus. Not in the sensational way the startup world talks about "organoid intelligence," but in the quieter way real revolutions always begin, through tools that work better than whatever came before them. Organoids aren't going to run computers. Some companies are making outlandish claims, and while my team and I are still digging in, I'd highly caution you to be extremely suspicious of "organic AI computer" claims. The consensus is these organoids aren't going to outthink silicon. But they're already doing something silicon can't do: they model human biology with human accuracy. They reveal how neurons migrate, how circuits form, how mutations derail development, and how a simple intervention can reverse that derailment. No mouse or petri dish has ever done that well. That makes organoids a new kind of economic engine.  Every drug that failed because the animal model wasn't human enough now has a second chance. Every neurological disorder that used to take decades to understand can be studied in months. Companies can grow organoids from a patient's own skin cells and test treatments on their neural tissue before ever touching their body. This isn't science fiction. It's the start of a new infrastructure. Labs can now grow trays of organoids at scale. Some hold dozens at a time. Some are built to connect them, stimulate them, record them, and stress-test them just like you would any other living system. The research that once required a lifetime now fits on a shelf. And that's where the real economic story sits. The industries built on long timelines, neurology, psychiatry, pain management, and developmental disorders, are about to collide with an acceleration they've never had. And the AI, energy, and infrastructure buildouts we've been discussing in these pages of Moonshot Minute will only accelerate what's already happening at lightning speed. Discoveries that once took twenty years may take two. The cost curves will collapse, then collapse again, and the companies supplying the tools, diagnostics, and datasets will become the new picks-and-shovels of cognitive biology. Organoids may never think. But they will help us understand thinking. And the markets that emerge from that understanding will be measured not in quarters or cycles, but in the decades of human potential they unlock. Where the Line Between Model and Mind Begins to Blur The deeper you go into the research, the harder it becomes to pretend this is only a scientific story. At some point, it turns into a human one. A moral one. A question of what happens when the ingredients of thought start behaving in ways we once believed required a person. Scientists in the NYT piece are careful about language. They repeat it often. These are organoids, not brains. They do not think, feel, or remember. They have no identity. They have no awareness. They are models built to help us study what real brains do, not replicas waiting to become one. But the fact that researchers have to clarify this so explicitly tells you something. The line is still firm. It is also closer than it used to be. Some of the world's top neuroscientists are calling for global oversight. Not because organoids are conscious now, but because the pace of progress is outpacing our definitions. If a system can wire itself, respond to stimuli, correct errors, synchronize signals, and mature for seven years, we owe it to ourselves to ask what comes next. The most grounded researchers in the article say the same thing. Consciousness is not on the table. But memory might be, someday. Or continuity. Or the faintest form of experience. And if those doors ever open, even a crack, the consequences won't stay in the lab. They'll shape medicine, ethics, law, and identity. The more these organoids grow, the more they shift the question. Instead of "Can they think?" the better question becomes "How close are we to systems that one day might?" No one knows the answer. But it's the kind of uncertainty we only get at the beginning of something big. And after reading the NYT story, it's clear we're already standing at the edge of it. 🚀 Get Moonshot Alerts Instantly Markets move in minutes. Your inbox can't keep up. Join the Moonshot VIP Text Service and get real-time alerts, portfolio updates, and first-move intelligence directly to your phone. Be first to know. Anywhere. 👉 [Join the Text List →] Standing at the Edge Before the World Has a Name for It On Wednesday, we talked about time becoming undervalued. Now we're looking at something even stranger. Time is stretching, and the ingredients of thought are learning in dishes. Two quiet revolutions are moving toward each other. One expands how long we can live. The other explores how the mind might one day be repaired, reset, or rebuilt. If longevity is the honest game of years, organoid research might be the honest game of understanding what those years are made of. And the early signals rarely show up in headlines. They show up in places like a quiet Harvard hallway filled with seven-year-old neuron clusters that aren't alive in any human sense, but aren't simple biology either. This is what it feels like to stand at the edge of a new field before it has a name. And if you understand these transitions early, you see where the capital, talent, and breakthroughs will converge long before the rest of the world does. Earlier this month, we made a major upgrade for our Moonshot Minute Premium members: a new institutional data system tracking the global infrastructure buildout. Today, we added another institutional research platform dedicated to biotech and longevity. It tracks the labs, trials, and emerging companies pushing these frontiers forward. Premium members don't pay extra for it. It's included.  I'm serious about helping individual investors compete with institutions, so my team and I need to arm them with the same intelligence. We are already having internal conversations about raising the price of Moonshot Premium to reflect these investments. But every current member, and anyone who joins before any change is announced, will be grandfathered in for life as long as their membership stays active. If you've been wondering when to join, this is that moment. The frontier is shifting fast. And the people who benefit most from these transitions are the ones who see the pattern before the world names it. Time keeps expanding. Understanding is catching up. And if you can hold both, you won't just keep pace with the future. You'll help shape it. Double D 🔓 Premium Content Begins Here 🔒 In today's Premium Section, an update on one of our favorite miners, where we're up 25% since August and why now is the time to get in if you haven't. I hope you've been paying attention because many of our picks are currently beating the S&P by up to 4-to-1 this year. Most financial newsletters charge $500, $1,000, even $5,000 per year. Why? Because they know they can. I don't. I built my wealth the old-fashioned way, not by selling subscriptions. That's why I priced this at $25/month, or $250/year. Not because it's low quality, but because I don't need to charge the typical prices other newsletters charge. One good trade, idea, or concept could pay for your next decade of subscriptions. The question isn't 'Why is this so cheap?' The question is, 'Why would I charge more?' 👉 Upgrade to Premium Now P.S. If this newsletter were $1,000 per year, you'd have to think about it. You'd weigh your options. You'd analyze the risk. But it's $25 a month. That's the price of a bad lunch decision. And remember, just one good idea could pay for your subscription for a decade. 👉 Upgrade to Premium Now   Update your email preferences or unsubscribe here © 2025 Moonshot Minute 228 Park Ave S, #29976, New York, New York 10003, United States Terms of Service